Skip Navigation LinksHome > December 2013 - Volume 56 - Issue 12 > Local Excision After Preoperative Chemoradiotherapy for Rect...
Diseases of the Colon & Rectum:
doi: 10.1097/DCR.0b013e3182a2303e
Original Contributions: Colorectal/Anal Neoplasia

Local Excision After Preoperative Chemoradiotherapy for Rectal Cancer: Results of a Multicenter Phase II Clinical Trial

Pucciarelli, Salvatore M.D.1; De Paoli, Antonino M.D.2; Guerrieri, Mario M.D.3; La Torre, Giuseppe M.D.4; Maretto, Isacco M.D.1; De Marchi, Francesco M.D.5; Mantello, Giovanna M.D.6; Gambacorta, Maria Antonietta M.D.7; Canzonieri, Vincenzo M.D.8; Nitti, Donato M.D.1; Valentini, Vincenzo M.D.7; Coco, Claudio M.D.9

Collapse Box

Abstract

BACKGROUND: Transanal local excision has been suggested as an attractive approach for patients with rectal cancer who show a major clinical response after preoperative chemoradiotherapy.

OBJECTIVE: To evaluate the impact of transanal local excision on the local recurrence of rectal cancer in patients who had a major clinical response after preoperative chemoradiotherapy.

DESIGN: Sequential 2-stage phase II study for early efficacy.

SETTING: Multicenter study.

PATIENTS: Patients with clinical T3 or low-lying T2 rectal adenocarcinoma that showed a major clinical response after a preoperative chemoradiotherapy. Eligible patients underwent a full-thickness transanal local excision. According to their histopathology, the patients staged as ypT0-1 were observed, while the remaining patients were recommended to undergo a subsequent total mesorectal excision.

MAIN OUTCOME MEASURES: A local recurrence rate of ≤5% was set as a successful rate for stopping the trial early after the first stage.

RESULTS: The study group included 63 patients. Before chemoradiotherapy, patients were staged as clinical T3 (n = 42) and T2 (n = 21). After the local excision, 43 patients fulfilled the criteria to be observed with no further treatment. Nine of the remaining 20 patients for whom a subsequent total mesorectal excision was recommended refused surgery. Two of these patients who refused surgery had intraluminal local recurrence; both had a ypT2 tumor and underwent salvage surgery. The estimated cumulative 3-year overall survival, disease-free survival and local disease-free survival were 91.5% (95% CI: 75.9–97.2), 91.0% (95% CI: 77.0–96.6) and 96.9% (95% CI: 80.3–99.5), respectively.

LIMITATIONS: The time of follow-up is still short and the sample size is limited.

CONCLUSIONS: Our data suggest that local excision is a good option for patients with a major clinical response after chemoradiotherapy. A longer period of follow-up is required to confirm these findings.

© 2013 The American Society of Colon and Rectal Surgeons

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.